Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Apellis Pharmaceuticals (APLS) PT Lowered to $75 at Raymond James
March 3, 2025 7:56 AM ESTRaymond James analyst Steven Seedhouse lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $75.00 (from $78.00) while maintaining a Strong Buy rating.
The analyst comments "We reiterate our Strong Buy rating on APLS following 4Q24 earnings. Given sales were pre-announced during JPM (see our... More
Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8c
February 28, 2025 7:11 AM ESTApellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of ($0.29), $0.08 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $212.5 million versus the consensus estimate of $192.9 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
... More